Close Menu

10x Genomics: Paul Conley

Dec 11, 2019

Paul Conley has resigned from 10x Genomics' board of directors, effective immediately. In a document filed with the US Securities and Exchange Commission, 10x said Conley's decision "was due solely to time commitments and a personal decision to pursue other business opportunities and is not due to any disagreement with the company's management team, operations, financial statements, policies, or procedures."

More Like This

Aug 06, 2020

Crown Bioscience: John Gu

Crown Bioscience has been appointed John Gu as chief operations officer. Gu joins Crown Bio from WuXi Nextcode, where he was general manager for the China business and chief digital officer. Prior to WuXi, Gu was held successive senior technology and operations roles across digital and technology companies, including Alcatel-Lucent. 

Aug 05, 2020

Integrity Laboratories: Maria Cekanova

Integrity Laboratories has appointed Maria Cekanova its chief scientific officer. She was previously director of translational research laboratory and research associate professor of oncology in the department of small animal clinical sciences at the University of Tennessee. Integrity received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 Assay.

Aug 04, 2020

Lexogen: Stéphane Barges, Alexander Seitz

Sequencing firm Lexogen has appointed Stéphane Barges as CEO, effective Sept. 1. 

Barges comes to Lexogen from Qiagen, where he was VP of molecular diagnostics. He has 20 years of experience in the life science and clinical diagnostics industry, including management positions at Life Technologies, Bio-Rad Laboratories, and Tecan. He holds a doctorate in genetics and molecular biology from the University of Geneva and an MBA from HEC Geneva.

Barges will succeed Lexogen founder Alexander Seitz, who will take on the role of chief innnovation officer.

Jul 31, 2020

Talis Biomedical: Roger Moody, Kim Popovits, Walter Koch

Talis Biomedical has named Roger Moody as CFO, while Kim Popovits has joined the company's board and Walter Koch has joined its scientific advisory board.

Moody was formerly CFO of Clinical Genomics. He previously was chief executive and COO at Glysure and CFO of Nanosphere and Medsn. Popovits is the former chairman of the board, president, and CEO of Genomic Health, which was acquired by Exact Sciences. She also held several management positions at Genentech, now part of Roche. Koch was at Roche Molecular Systems where he held several leadership roles, including vice president and head of global research. Prior to that, he was at the US Food and Drug Administration.

Jul 30, 2020

ACMG Foundation for Genetic and Genomic Medicine: Nasha Fitter

The ACMG Foundation for Genetic and Genomic Medicine, a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice, has elected Nasha Fitter to its board of directors. Fitter currently serves as director of Rare and Neurological Diseases at Ciitizen. She is also cofounder, CEO, and head of research at FOXG1 Research Foundation, an organization focused on finding a cure for FOXG1 syndrome. Previously, Fitter founded and served as CEO of Schoolie, and prior to that worked as director of the Global Schools Program at Microsoft Education.

Jul 29, 2020

Agendia: Brian Dow

Agendia has appointed Brian Dow as CFO. Prior to this position, he served as senior VP and CFO of Pulse Biosciences, where he was responsible for executing the company's early-stage IPO and subsequent follow-on offerings. Before that, he was CFO at Progyny, and prior to that, he was VP and principal accounting officer at Pacific Biosciences. Previously, he also worked for Ernst & Young. Dow holds a bachelor's degree from Georgia Institute of Technology.

Jul 28, 2020

Aegea Biotechnologies: George Maltzeos

Aegea Biotechnologies said that it has hired George Maltzeos as chief engineer to help expedite the development of the company's point-of-care lateral flow molecular SARS-CoV-2 test being developed in collaboration with Tauriga Sciences. Maltzeos previously served as director of the California Institute of Technology Global Health Initiative where he helped secure $4.5 million in funding from the Bill & Melinda Gates Foundation to develop point-of-care clinical diagnostics for developing countries. He also previously founded and served as chief engineer for Helixis, which was acquired by Illumina in 2010. Maltzeos holds a PhD in electrical engineering from CalTech and a BS from Columbia University.

Jul 28, 2020

Clinical Genomics: Michael Paris, Zivjena Vucetic, Edward Rosen

Clinical Genomics has appointed Michael Paris as chief operating officer, Zivjena Vucetic as senior VP, medical, and Edward Rosen as chief strategy and commercial officer.

Paris most recently served as COO and senior VP, operations and technology development, at Origin. Prior to Origin, he served in several positions at Bioconnect Systems, Orthovita, and Rex Medical. 

Before Clinical Genomics, Vucetic served as medical director at Ortho-Clinical Diagnostics. Prior to that, she held multiple scientific and medical roles at Fujirebio Diagnostics. 

Rosen most recently served as an executive in residence at Columbia University. Prior to Columbia, he held several research roles at Johnson & Johnson. 

Jul 28, 2020

Meridian Bioscience: Anthony Bihl

Meridian Bioscience announced the appointment of Anthony Bihl to its board of directors, effective immediately. Bihl retired in April as CEO of Bioventus and was previously the CEO of American Medical Systems and CEO of Siemens Medical Solutions Diagnostics. He has also served in senior executive roles at Bayer Healthcare's diagnostics division and in multiple operations and finance roles at Dupont.

Jul 27, 2020

Veracyte: Jens Holstein, James Erlinger

Veracyte has appointed Jens Holstein to its board of directors and James Erlinger as executive VP, general counsel, and secretary.

Holstein was appointed as CFO of MorphoSys in 2011. Prior to MorphoSys, he served as regional CFO of the Europe/Middle East region for Fresensius Kabi, a subsidiary of Fresenius. He has also held several other leadership roles within the Fresenius group. 

Erlinger previously served as executive VP, general counsel, and secretary of Iqvia. He spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner. 

Jul 24, 2020

SeqBiome: Marcus Claesson, Paul Cotter, Brad Wrigley

University College Cork spinout SeqBiome announced its management team this week. Marcus Claesson is the company's CEO, Paul Cotter is the firm's chief technology officer, and Brad Wrigley is executive director.

Claesson is a principal investigator at APC Microbiome Ireland. He has a PhD in bioinformatics from the National University of Ireland and an MSc in bioinformatics, as well as a BSc in chemical engineering and physics, from Chalmers University of Technology in Gothenburg, Sweden.

Cotter is head of food biosciences at Teagasc and a principal investigator with APC Microbiome Ireland, Vistamilk SFI Centres, and Food for Health Ireland. He holds PhD and BSc degrees in microbiology from University College Cork.

Wrigley has been working with several startup and spinout companies. He has more than 20 years of experience as a director, entrepreneur, investor, and CEO in government and industry, including at Accenture, Dell EMC, and Virtustream.

Jul 24, 2020

Cradle Genomics: Tanya Moreno, Sue Gross

Prenatal diagnostics firm Cradle Genomics has appointed Tanya Moreno as VP of development and Sue Gross as chief medical officer.

Moreno has 13 years of experience in diagnostics development and the commercialization of genomic tests. She holds a PhD in molecular genetics and developmental biology from the California Institute of Technology.

Gross joins the company from Sema4, where she was medical director for the reproductive lab and clinical analysis division. Previously, she was chief medical officer at Natera, and before that, professor of obstetrics and gynecology, pediatrics, and genetics at Montefiore Einstein. She is a physician with board certifications in obstetrics and gynecology as well as medical genetics.

Jul 23, 2020

Twist Bioscience: Erin Smith

Twist Bioscience has appointed Erin Smith to the newly created position of senior VP of government affairs and public policy.

According to federal disclosure records, Smith registered as a lobbyist for Twist in December 2019, while at Smith Capitol Strategies. She is also an adjunct faculty member of the University of Houston Law Center.

Prior to Twist, Smith worked at Gilead Sciences, where she expanded the firm's lobbying efforts. Before that, she was an advisor to former Secretary of Energy and former Governor of Texas Rick Perry.

Smith holds a JD from the University of Houston Law Center and a master of public health degree from the University of Texas Health Science Center.

Jul 22, 2020

Myriad Genetics: Walter Gilbert, Daniel Skovronsky

Myriad Genetics has expanded its board of directors to 10 members with the election of Daniel Skovronsky, CSO and president of Lilly Research Laboratories at Eli Lilly. Skovronsky will serve on the research and product innovation committee within Myriad’s board. Additionally, Myriad announced that Walter Gilbert, the director and vice chair of the board, will retire from these positions at the firm's annual stockholder meeting in December. Gilbert cofounded Myriad and received a Nobel Prize in chemistry in 1980 for his development of rapid DNA sequencing technology. 

Jul 22, 2020

Biodesix: Jean Franchi, Hany Massarany

Biodesix has appointed Jean Franchi and Hany Massarany to its board of directors. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.

Franchi currently serves as chief financial officer for Replimune Group, a biotechnology company developing oncolytic immuno-gene therapies. She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme. She holds a bachelor's degree in business administration from Hofstra University.

Massarany served as president and chief executive officer of GenMark Diagnostics from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009 he was responsible for various global leadership positions with Ventana. He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University and an MBA from Melbourne University.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.